Affinage

CEBPB

CCAAT/enhancer-binding protein beta · UniProt P17676

Length
345 aa
Mass
36.1 kDa
Annotated
2026-06-09
100 papers in source corpus 40 papers cited in narrative 40 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CEBPB (C/EBPβ / NF-IL6) is a bZIP transcription factor that binds CCAAT/enhancer core elements as sequence-specific homo- or heterodimers to activate or repress genes governing inflammation, myeloid differentiation, adipogenesis, liver regeneration, and stress responses (PMID:2112087, PMID:7557387). As a direct transcriptional regulator it activates pro-inflammatory and acute-phase targets including IL-6, TNFα, iNOS, and SerpinB2/PAI-2 (PMID:2112087, PMID:7929820, PMID:23472114, PMID:11834703), drives the adipogenic cascade by inducing PPARγ in synergy with glucocorticoid signaling (PMID:7557387), and acts as a repressor of targets such as the albumin gene during liver regeneration and CD200R1 in activated microglia, where repression is mediated by recruitment of HDAC1 (PMID:8703043, PMID:22776069). Beyond direct DNA binding, C/EBPβ functions through protein–protein partnerships: its full-length N-terminal domain recruits the SWI/SNF chromatin-remodeling complex to activate myeloid genes (PMID:10619021), it cooperates with c-Myb through long-range DNA looping demonstrated structurally (PMID:11792321), and it forms functional complexes with the glucocorticoid receptor, PGC1α, Elk-1, NF-κB p65, and CHOP to integrate hormonal, metabolic, and stress inputs (PMID:18650268, PMID:30945396, PMID:11151091, PMID:16785565, PMID:20479126). C/EBPβ activity is heavily controlled post-transcriptionally and post-translationally: it is converted from repressor to activator by MAPK/Ras-, RSK-, GSK-3β-, and PKA/CREB-driven phosphorylation that also dictates selective association with active versus inactive Mediator complexes and subnuclear relocalization (PMID:14759369, PMID:12821655, PMID:9199295, PMID:22080951, PMID:18159255), and the LAP and LIP isoforms produced by isoform-specific translational control exert opposing effects on ER-stress-induced apoptosis, multidrug resistance, and cell-cycle progression (PMID:20479126, PMID:20209087, PMID:25766403, PMID:15368440). Its abundance is further set by ubiquitin-, autophagy-, and translation-dependent turnover that tunes immune polarization and inflammatory output (PMID:25766403, PMID:37963021, PMID:21389327). In myeloid cells C/EBPβ is required for emergency generation of immunosuppressive MDSCs and for the switch from a pro-inflammatory to a repressor phenotype during sepsis and tumor-associated immune suppression (PMID:28476751, PMID:29805099). Disease-linked roles include a δ-secretase-cleaved APP fragment that binds and hyperactivates CEBPB to amplify Alzheimer's disease pathology (PMID:33880508).

Mechanistic history

Synthesis pass · year-by-year structured walk · 40 steps
  1. 1990 High

    Established the molecular identity of CEBPB as a sequence-specific bZIP activator, answering what kind of protein mediates IL-6-responsive enhancer activity.

    Evidence expression cloning, bacterial fusion-protein DNA binding, and reporter transactivation of the IL-6 promoter

    PMID:2112087

    Open questions at the time
    • No in vivo target spectrum defined
    • Regulation of its activity not yet addressed
  2. 1992 Medium

    Showed CEBPB activity is controlled post-translationally, answering how IL-6 acutely boosts its function without new synthesis.

    Evidence identity comparison with IL-6DBP and DNA-binding assays after IL-6 stimulation

    PMID:1380488

    Open questions at the time
    • Specific phosphorylation site not mapped
    • Responsible kinase not identified
  3. 1994 Medium

    Defined CEBPB as a direct macrophage TNFα activator, distinguishing it functionally from C/EBPα.

    Evidence cotransfection reporter assays with a dominant-negative C/EBPβ and DNA binding

    PMID:7929820

    Open questions at the time
    • No endogenous knockout validation
    • Site occupancy in vivo not shown
  4. 1996 High

    Demonstrated CEBPB can act as a direct repressor, broadening its role beyond activation during liver regeneration.

    Evidence in vitro transcription with recombinant LAP, EMSA on the albumin D site, and hepatectomy model

    PMID:8703043

    Open questions at the time
    • Corepressor machinery not identified
    • Isoform-specific contribution to repression unresolved
  5. 1997 High

    Identified the PKA/CREB pathway as an upstream regulator of CEBPB gene expression, linking cAMP signaling to its transcription.

    Evidence promoter deletion/mutagenesis, EMSA/supershift of CRE sites, and liver regeneration model

    PMID:9199295

    Open questions at the time
    • Other inducible inputs to the promoter not enumerated
  6. 1995 High

    Placed CEBPB upstream in the adipogenic cascade, answering what initiates PPARγ induction during preadipocyte commitment.

    Evidence tetracycline-regulated conditional expression in NIH-3T3 with PPARγ readouts and differentiation assays

    PMID:7557387

    Open questions at the time
    • Direct vs indirect PPARγ promoter occupancy not resolved here
    • Glucocorticoid synergy mechanism unclear
  7. 1999 High

    Revealed that full-length CEBPB recruits a chromatin-remodeling machine, explaining isoform-specific activation in a chromatin context.

    Evidence interaction assays plus domain-swap chimera reconstituting SWI/SNF recruitment and mim-1 transcription

    PMID:10619021

    Open questions at the time
    • SWI/SNF subunit contacted not defined
    • Generalizability beyond myeloid genes untested
  8. 2000 Medium

    Showed Ras-dependent partnership with Elk-1, connecting CEBPB to growth-factor-induced immediate-early transcription.

    Evidence GST pulldown, Ras-dependent co-IP, and SRE reporter assays with domain mapping

    PMID:11151091

    Open questions at the time
    • Endogenous SRE occupancy not shown
    • Single-lab interaction
  9. 2002 High

    Provided structural evidence for long-range cooperativity with c-Myb, explaining combinatorial promoter activation and v-Myb's defect.

    Evidence X-ray crystallography of ternary complexes, GST pulldown, AFM, and luciferase assays

    PMID:11792321

    Open questions at the time
    • In vivo relevance of DNA looping not quantified
  10. 2002 Medium

    Linked CEBPB to hypoxia-induced iNOS transcription in vascular smooth muscle.

    Evidence iNOS promoter C/EBP-site mutation, EMSA, and hypoxia exposure

    PMID:11834703

    Open questions at the time
    • No loss-of-function validation
    • Upstream hypoxia signaling to CEBPB unmapped
  11. 2003 High

    Established phosphorylation-driven subnuclear relocation, showing MAPK signaling repositions CEBPB to heterochromatin.

    Evidence immunofluorescence, phospho-site antibody, MEK inhibition, and satellite-DNA binding after GH stimulation

    PMID:12821655

    Open questions at the time
    • Functional consequence of pericentromeric targeting unclear
    • Heterochromatin target genes unknown
  12. 2004 High

    Defined a Ras/MAPK conformational switch that toggles CEBPB between repressive and active Mediator complexes, providing a molecular mechanism for activity control.

    Evidence co-IP, RNAi of CRSP130/Sur2, activating mutations, and reporter assays

    PMID:14759369

    Open questions at the time
    • Structural basis of the conformational change not solved
    • Which target genes use each Mediator form not enumerated
  13. 2004 High

    Identified IGF-I as a direct survival target through which CEBPB enables oncogenic macrophage transformation.

    Evidence C/EBPβ-null cells with genetic rescue, IGF-I promoter reporter, and in vivo tumorigenicity

    PMID:15060147

    Open questions at the time
    • Direct promoter occupancy by ChIP not shown
  14. 2004 Medium

    Showed LAP and LIP isoforms differentially set cell-cycle timing in regenerating liver, establishing isoform-specific functional divergence.

    Evidence adenoviral isoform overexpression in partial hepatectomy with cyclin/CDK2 readouts

    PMID:15368440

    Open questions at the time
    • Direct vs indirect cyclin regulation unclear
    • Single-lab in vivo overexpression
  15. 2005 High

    Established a neuronal regeneration role, showing CEBPB is required for injury-induced regeneration-associated gene transcription.

    Evidence C/EBPβ-null mice with Tα1 promoter reporter transgenes and facial nerve injury

    PMID:15936952

    Open questions at the time
    • Upstream injury signaling to CEBPB not defined
  16. 2006 High

    Revealed an anti-inflammatory braking function through complex formation with NF-κB p65, blocking p65 phosphorylation during TNF tolerance.

    Evidence C/EBPβ-null cells, reciprocal co-IP, phosphorylation and reporter assays

    PMID:16785565

    Open questions at the time
    • Phosphatase or kinase blocked not identified
    • Direct vs scaffolded inhibition unresolved
  17. 2006 Medium

    Showed CEBPB is a differentiation-promoting target silenced translationally by BCR/ABL, linking its loss to leukemic block.

    Evidence BCR/ABL model, imatinib reinduction, CUGBP1 dependence, and DNA-binding-deficient mutant

    PMID:16418324

    Open questions at the time
    • Direct CUGBP1-mRNA contact not mapped here
    • Differentiation target genes unspecified
  18. 2006 Medium

    Implicated CEBPB as the effector of a fusion oncogene-driven IL-6 program in liposarcoma.

    Evidence siRNA epistasis and ChIP of CEBPB at the IL-6 promoter

    PMID:15688424

    Open questions at the time
    • Mechanism of FUS-DDIT3 activation of CEBPB unresolved
  19. 2007 High

    Defined RSK phosphorylation of CEBPB as a fibrosis-driving survival switch in hepatic stellate cells.

    Evidence phospho-null C/EBPβ-Ala217 transgenic mice, CCl4 model, caspase-8 complex IP, and RSK-inhibitory peptide

    PMID:18159255

    Open questions at the time
    • How phosphorylation excludes CEBPB from death complex II mechanistically unclear
  20. 2008 High

    Demonstrated GR–CEBPB cooperation drives corticosteroid-induced COX-2, integrating glucocorticoid signaling at a shared promoter.

    Evidence co-IP, ChIP, COX-2 promoter mutagenesis, and siRNA knockdown

    PMID:18650268

    Open questions at the time
    • Stoichiometry of the GR-CEBPB complex unknown
  21. 2010 High

    Showed the LIP isoform chaperones CHOP into the nucleus and amplifies ER-stress apoptosis, defining an isoform-specific pro-death function.

    Evidence C/EBPβ-null MEFs reconstituted with LIP, co-IP, fractionation, and apoptosis assays

    PMID:20479126

    Open questions at the time
    • Import receptor used for LIP-CHOP transit not identified
  22. 2010 Medium

    Established opposing LAP/LIP roles in tumor ER-stress survival, with LAP protecting and LIP sensitizing cells.

    Evidence inducible isoform overexpression with orthotopic tumors and UPR/cell-death markers

    PMID:20209087

    Open questions at the time
    • Direct UPR target genes per isoform not defined
  23. 2011 High

    Captured an evolutionary rewiring of CEBPB phosphoregulation, showing how its GSK-3β/PKA response was reversed in placental mammals.

    Evidence ancestral protein resurrection with site-directed mutagenesis and functional phospho assays

    PMID:22080951

    Open questions at the time
    • Physiological target genes affected by the rewiring not mapped
  24. 2011 Medium

    Identified eIF4E-dependent translational control of CEBPB as the basis of IMiD anti-myeloma action and linked CEBPB to IRF4 regulation.

    Evidence stability/mRNA exclusion experiments, eIF4E manipulation, rescue, and patient sampling

    PMID:21389327

    Open questions at the time
    • Direct IRF4 promoter occupancy not shown here
    • Single-lab translational mechanism
  25. 2012 High

    Defined an HDAC1-dependent repressive complex through which CEBPB silences CD200R1 in activated microglia.

    Evidence qChIP, co-IP of HDAC1-CEBPB, null primary microglia, and HDAC inhibitor reversal

    PMID:22776069

    Open questions at the time
    • Other corepressors not excluded
  26. 2013 High

    Established CEBPB as a direct activator of both constitutive and LPS-induced SerpinB2 in macrophages.

    Evidence C/EBPβ-null MEFs/macrophages, EMSA, ChIP, and promoter mutagenesis

    PMID:23472114

    Open questions at the time
    • Cooperating LPS-responsive factors not defined
  27. 2015 Medium

    Showed cytosine modifications tune CEBPB DNA binding, with 5hmC selectively inhibiting it in an isoform-specific manner.

    Evidence systematic EMSA across all CG modification states with CD validation

    PMID:25779641

    Open questions at the time
    • In vivo relevance at endogenous loci not tested
  28. 2015 Medium

    Linked ubiquitin-driven lysosomal/proteasomal LIP degradation to multidrug resistance through Pgp and the CHOP-caspase-3 axis.

    Evidence ubiquitination assays, degradation inhibitors, and LIP rescue in vitro and in vivo

    PMID:25766403

    Open questions at the time
    • E3 ligase responsible for LIP ubiquitination unidentified
  29. 2017 High

    Established a myeloid-intrinsic requirement for CEBPB in sepsis-driven MDSC generation and immunosuppression.

    Evidence myeloid-specific conditional knockout, sepsis model, adoptive transfer, and MDSC profiling

    PMID:28476751

    Open questions at the time
    • Direct CEBPB target genes mediating the repressor switch not enumerated
  30. 2018 Medium

    Connected tumor metabolism to immunosuppression through an AMPK-ULK1-autophagy axis controlling the LAP isoform and downstream G-CSF/GM-CSF.

    Evidence glycolysis inhibition, pathway manipulation, isoform-specific blots, and TNBC mouse models

    PMID:29805099

    Open questions at the time
    • Mechanism of autophagy-dependent isoform control unclear
  31. 2019 Medium

    Identified PRMT7 methylation of CEBPB as a brake on its adipogenic promoter occupancy.

    Evidence co-IP, methylation assay, ChIP at PPARγ2 promoter, and PRMT7-null MEFs

    PMID:31371025

    Open questions at the time
    • Methylated residues not mapped
  32. 2019 Medium

    Showed DN-ATF5 sequesters CEBPB by blocking dimer formation, and that CEBPB knockdown is selectively lethal to cancer cells.

    Evidence pull-down mass spectrometry, immunoblot, siRNA, and reporter assays

    PMID:31676720

    Open questions at the time
    • Cancer-specific dependency mechanism unresolved
  33. 2019 Medium

    Defined a PGC1α-CEBPB partnership driving CPT1A transcription and fatty-acid-oxidation-dependent radioresistance.

    Evidence co-IP, ChIP/reporter for CPT1A, FAO assay, and radiation-resistance readouts

    PMID:30945396

    Open questions at the time
    • Direct vs cooperative promoter binding not fully resolved
  34. 2019 Medium

    Linked PAK4 phosphorylation of CEBPB Thr-235 to CLDN4 activation and breast cancer invasion.

    Evidence ChIP at the CLDN4 promoter, phosphorylation assay, siRNA, and migration/invasion assays

    PMID:30808546

    Open questions at the time
    • Effect of phosphorylation on DNA binding vs activity unclear
  35. 2021 Medium

    Revealed a δ-secretase-truncated APP fragment as a direct CEBPB activator amplifying Alzheimer's pathology.

    Evidence co-IP, nuclear translocation and reporter assays, viral mouse model, and antibody clearance

    PMID:33880508

    Open questions at the time
    • Binding interface on CEBPB not mapped
    • Single-lab in vivo model
  36. 2022 Medium

    Identified NRF2 as a direct regulator of CEBPB and a co-regulatory partner driving detoxification-linked drug resistance.

    Evidence ChIP-seq, transcriptomics with CEBPB knockout, and drug-resistance assays

    PMID:35137113

    Open questions at the time
    • Functional separability of NRF2 vs CEBPB contributions limited
  37. 2022 Medium

    Placed CEBPB upstream of the TRIM2/p53 axis as an epinephrine-responsive regulator destabilizing p53.

    Evidence ChIP at TRIM2 promoter, co-IP, p53 ubiquitination assay, and β2-adrenergic antagonist

    PMID:35672760

    Open questions at the time
    • Direct vs indirect epinephrine-to-CEBPB link incomplete
  38. 2022 Medium

    Showed CEBPB drives Pim-1-dependent NLRP3 inflammasome activation and podocyte pyroptosis in lupus nephritis.

    Evidence ChIP at Pim-1 promoter, in vivo shCEBPB, and Pim-1 overexpression rescue in MRL/lpr mice

    PMID:36248187

    Open questions at the time
    • Upstream signal activating CEBPB in podocytes unclear
  39. 2023 High

    Established that autophagy controls macrophage M2 polarization by degrading CEBPB, which otherwise drives SOCS1/3 to suppress JAK1-STAT6.

    Evidence macrophage-specific Atg5 conditional KO, CEBPB ChIP at SOCS1/3, and STAT6 phosphorylation readouts

    PMID:37963021

    Open questions at the time
    • p62 recognition motif on CEBPB not defined
  40. 2024 Medium

    Defined a CEBPB-SERPINA1-STAT3 axis promoting colorectal cancer progression.

    Evidence ChIP, luciferase reporter, and CRC functional assays

    PMID:38710698

    Open questions at the time
    • Direct vs indirect STAT3 activation unresolved

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the many context-specific phosphorylation, methylation, and degradation inputs are integrated to select between CEBPB's activating and repressive output programs at the genomic level remains unresolved.
  • No genome-wide map reconciling isoform, modification state, and target choice
  • Structural basis of the repressor-to-activator conformational switch unsolved
  • E3 ligases and the full degradation network controlling each isoform incompletely defined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 6 GO:0003677 DNA binding 5 GO:0060089 molecular transducer activity 4
Localization
GO:0005634 nucleus 4 GO:0000228 nuclear chromosome 1 GO:0005829 cytosol 1
Pathway
R-HSA-168256 Immune System 5 R-HSA-5357801 Programmed Cell Death 4 R-HSA-74160 Gene expression (Transcription) 4 R-HSA-1266738 Developmental Biology 3 R-HSA-8953897 Cellular responses to stimuli 3
Partners
ATF5CHOP/DDIT3ELK1HDAC1MYBNFKB1/RELANR3C1PPARGC1A

Evidence

Reading pass · 40 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1990 NF-IL6 (CEBPB) was cloned and identified as a member of the C/EBP family of bZIP transcription factors; the bacterially expressed protein binds CCAAT homology and viral enhancer core sequences and activates the human IL-6 promoter in a sequence-specific manner. The protein contains a leucine zipper domain and shares high homology with C/EBP at the C-terminal DNA-binding domain. Lambda gt11 library screening with NF-IL6 binding sequence, bacterial fusion protein DNA-binding assay, transfection reporter assay The EMBO journal High 2112087
1992 NF-IL6 (CEBPB) is identical to IL-6DBP, the DNA-binding protein responsible for IL-6-mediated induction of acute-phase proteins. Post-translational modification (phosphorylation) increases NF-IL6 DNA-binding activity after IL-6 stimulation without increasing protein synthesis, demonstrating post-translational regulation. Protein identity comparison, DNA binding activity assays, IL-6 stimulation without protein synthesis increase Immunological reviews Medium 1380488
1995 Conditional ectopic expression of C/EBPβ in NIH-3T3 fibroblasts induces PPARγ expression and converts cells into committed preadipocytes. C/EBPβ and dexamethasone synergize to activate PPARγ transcription; C/EBPβ alone or dexamethasone alone is insufficient, establishing C/EBPβ as an upstream activator of PPARγ in the adipogenic transcriptional cascade. Tetracycline-regulated conditional expression system, stable cell line, RT-PCR, reporter assays, adipogenic differentiation assays Genes & development High 7557387
1999 The N-terminal domain of the full-length C/EBPβ isoform (but not shorter isoforms) physically interacts with the SWI/SNF chromatin remodeling complex and recruits it to activate myeloid-specific genes (mim-1) in a chromatin context. Grafting this domain onto Myb reconstitutes SWI/SNF recruitment and mim-1 transcription in the absence of C/EBPβ. Protein interaction assays, domain swapping/chimeric activator, transcription assays in chromatin context Molecular cell High 10619021
2002 Crystal structures of ternary complexes containing c-Myb DBD, C/EBPβ DBD, and promoter DNA revealed that DNA-bound C/EBPβ interacts with R2 of c-Myb bound to a separate DNA fragment, with intervening DNA looping. Point mutations in v-Myb R2 that abolish this interaction explain why v-Myb cannot cooperate with C/EBPβ. GST pulldown, luciferase assays, and atomic force microscopy confirmed this long-range interaction. X-ray crystallography, GST pulldown, luciferase transactivation assay, atomic force microscopy Cell High 11792321
2004 Oncogenic Ras signaling phosphorylates a MAPK site in C/EBPβ, inducing a conformational change that switches C/EBPβ from a repressor to an activator. Active and repressive C/EBPβ both interact with Mediator complexes via the CRSP130/Sur2 subunit, but Ras signaling or activating mutations in C/EBPβ selectively induce association with the transcriptionally active (CRSP70-containing) Mediator complex rather than the inactive (CDK8-containing) Mediator complex. Knockdown of CRSP130/Sur2 prevents Mediator binding and transactivation. Co-immunoprecipitation, RNAi knockdown, reporter assays, conformational change analysis Molecular cell High 14759369
2003 Growth hormone (GH) rapidly relocates C/EBPβ from a diffuse nuclear distribution to pericentromeric heterochromatin in a MAPK-dependent manner. This relocation requires phosphorylation of C/EBPβ on a conserved MAPK consensus site (prevented by MEK inhibitor U0126). C/EBPβ (but not C/EBPδ) binds satellite DNA containing C/EBP sites in vitro, and GH transiently increases this binding in cells. Indirect immunofluorescence, MAPK-site-specific antibody, MEK inhibitor (U0126) treatment, DNA binding assay with satellite DNA, live cell fractionation The Journal of biological chemistry High 12821655
1997 CREB binds to two CRE sites in the LAP/C/EBPβ gene promoter and is required for both basal promoter activity and inducibility. The protein kinase A (PKA) pathway stimulates LAP/C/EBPβ transcription through CREB phosphorylation; mutation of CREB sites reduces promoter activity. In vivo, CREB phosphorylation correlates with LAP/C/EBPβ mRNA induction during liver regeneration. Deletion analysis, gel shift/EMSA, crosslinking, supershift, competition experiments, luciferase reporter with site-directed mutants, Northern blot, runoff transcription assay, hepatectomy model Molecular and cellular biology High 9199295
1994 C/EBPβ (NF-IL6) activates the TNFα gene promoter in cotransfection assays by binding a site that C/EBPα does not bind. A dominant-negative version of C/EBPβ blocks TNFα promoter activation in myeloid cells, establishing C/EBPβ as a direct transcriptional regulator of TNFα in macrophages. Cotransfection reporter assay, dominant-negative C/EBPβ, DNA binding assay The Journal of clinical investigation Medium 7929820
2011 Three amino acid substitutions in an internal regulatory domain of CEBPB in the stem lineage of placental mammals reorganized phosphorylation sites—introducing one new site and removing two ancestral sites—reversing the response of CEBPB to GSK-3β-mediated phosphorylation from repression to activation. Demonstrated by resurrecting ancestral CEBPB proteins and functionally testing their responses to cAMP/PKA signaling. Ancestral protein resurrection, functional phosphorylation assays, site-directed mutagenesis Nature High 22080951
2010 The C/EBPβ isoform LIP is required for nuclear translocation of CHOP during ER stress. In early ER stress, LIP undergoes proteasomal degradation in the cytoplasm; during later ER stress, LIP binds CHOP in both cytoplasmic and nuclear compartments and acts as a vehicle for CHOP nuclear import, while CHOP stabilizes LIP. LIP-expressing C/EBPβ-null MEFs showed enhanced ER stress-induced apoptosis and decreased Bcl-2. C/EBPβ-/- MEFs, LIP expression vectors, co-immunoprecipitation, subcellular fractionation, apoptosis assays, Western blot Molecular and cellular biology High 20479126
2010 C/EBPβ LAP isoform promotes tumor progression by attenuating ER stress-triggered cell death, while the LIP isoform augments ER stress-induced apoptosis. Inducible overexpression of LIP enhanced ER stress cell death, and LAP overexpression attenuated it, both in vitro and in vivo, operating through the unfolded protein response (UPR) without affecting cell cycle or angiogenesis. Inducible overexpression, orthotopic tumor implantation, ER stress markers, cell death assays PloS one Medium 20209087
2006 In TNF-tolerant monocytic cells, C/EBPβ forms complexes with NF-κB p65, specifically preventing p65 phosphorylation and thereby inhibiting NF-κB-mediated transcription. In C/EBPβ-/- cells under tolerance conditions, neither transcriptional inhibition nor p65 dephosphorylation occurs. Overexpression of C/EBPβ reduces p65-mediated transactivation. C/EBPβ-/- cell knockout, co-immunoprecipitation of C/EBPβ-p65 complex, phosphorylation assays, reporter assays, C/EBPβ overexpression Journal of immunology High 16785565
2007 RSK kinase phosphorylates C/EBPβ on Thr217 (Thr266 in human) in activated hepatic stellate cells (HSCs), and this phosphorylation is critical for liver fibrosis progression. Non-phosphorylatable C/EBPβ-Ala217 was found within the death receptor complex II with active caspase-8 and induced apoptosis of activated HSCs. An RSK-inhibitory cell-permeant peptide prevented fibrosis progression. Transgenic non-phosphorylatable C/EBPβ-Ala217 mice, CCl4 fibrosis model, death receptor complex immunoprecipitation, caspase-8 cell-free system, RSK-inhibitory peptide treatment PloS one High 18159255
2004 C/EBPβ is essential for oncogenic transformation of macrophages and promotes survival by directly transcriptionally activating IGF-I. Overexpression of C/EBPβ stimulated transcription from the IGF-I promoter; IGF-I acts as an autocrine survival factor in these tumor cells, and forced expression of either C/EBPβ or IGF-I in C/EBPβ-/- bone marrow cells restored Myc/Raf-induced transformation. C/EBPβ-/- macrophages, IGF-I neutralization, IGF-I-/- cells, C/EBPβ overexpression, IGF-I promoter reporter assay, in vivo tumor implantation Molecular and cellular biology High 15060147
2005 C/EBPβ is required for transcriptional activation of regeneration-associated genes (Tα1 α-tubulin and GAP-43) following axonal injury in facial motor neurons. Injury-induced upregulation of these genes was specifically inhibited in C/EBPβ-/- mice using minimal and full Tα1 promoter reporter constructs containing functional C/EBP binding sites. C/EBPβ-/- mice, transgenic reporter constructs with C/EBP binding sites, in situ hybridization, facial nerve injury model Molecular and cellular neurosciences High 15936952
1996 C/EBP-β/LAP directly down-regulates albumin gene transcription during liver regeneration. Increased nuclear C/EBPβ/LAP binds the D site of the albumin promoter and inhibits transcription as shown by in vitro transcription assays with recombinant C/EBPβ/LAP and liver nuclear extracts. Pre- and post-translational mechanisms contribute to rapid nuclear accumulation after hepatectomy. In vitro transcription assay, EMSA gel shift with albumin promoter D site, hepatectomy model, transfection assays The Journal of biological chemistry High 8703043
2011 IMiD compounds (pomalidomide, lenalidomide) down-regulate C/EBPβ protein through translational control dependent on eIF4E, without altering C/EBPβ mRNA levels or protein stability. C/EBPβ protein expression is under eIF4E translational control in multiple myeloma cells, and overexpression of C/EBPβ rescues cells from IMiD-induced anti-proliferative effects. C/EBPβ in turn transcriptionally regulates IRF4. Protein stability assays, mRNA stability assays, eIF4E manipulation, C/EBPβ overexpression rescue, reporter assays, longitudinal patient bone marrow sampling Blood Medium 21389327
2006 CEBPB expression is repressed in BCR/ABL-transformed myeloid cells through a translational mechanism dependent on the CUG-rich intercistronic region of C/EBPβ mRNA and the RNA-binding protein CUGBP1. Reinduction of CEBPB by imatinib or constitutive expression induced differentiation and inhibited proliferation of BCR/ABL cells; a DNA binding-deficient mutant had no effect, indicating the mechanism requires DNA binding. BCR/ABL cell model, imatinib treatment, CUGBP1 dependence assays, DNA binding-deficient mutant, in vitro and in vivo differentiation assays Blood Medium 16418324
2015 C/EBPβ DNA-binding activity is modulated by cytosine modifications: 5hmC in the CG dinucleotide of the C/EBP|CRE hybrid 8-mer specifically inhibits C/EBPβ binding, while 5mC, 5fC, and 5caC enhance binding. This 5hmC inhibition does not occur for C/EBPα, indicating an isoform-specific effect linked to structural differences between the two proteins. EMSA with all 25 CG modification states, circular dichroism thermal denaturation Biochimica et biophysica acta Medium 25779641
2008 Corticosteroids induce COX-2 expression in cardiomyocytes through a mechanism requiring both the glucocorticoid receptor (GR) and C/EBPβ. Corticosterone induces GR-C/EBPβ protein-protein interaction (demonstrated by co-IP), and both GR and C/EBPβ bind the COX-2 promoter (demonstrated by ChIP). siRNA against C/EBPβ prevents corticosterone-induced COX-2 promoter activation. Co-immunoprecipitation, ChIP assay, COX-2 promoter deletion/mutation, siRNA knockdown, GR antagonist mifepristone American journal of physiology. Cell physiology High 18650268
2012 C/EBPβ transcriptionally represses CD200R1 expression in LPS-stimulated microglial cells. C/EBPβ binds the CD200R1 promoter directly (confirmed by qChIP). Histone deacetylase 1 (HDAC1) co-immunoprecipitates with C/EBPβ and binds a C/EBPβ consensus sequence in the CD200R1 promoter in LPS-treated cells, and HDAC inhibitors reverse C/EBPβ-mediated CD200R1 repression. qChIP, co-immunoprecipitation of HDAC1 and C/EBPβ, C/EBPβ-/- primary microglia, C/EBPβ-overexpressing BV2 cells, HDAC inhibitors Journal of neuroinflammation High 22776069
2018 Glycolysis restriction in triple-negative breast cancer represses expression of the CEBPB isoform LAP (liver-enriched activating protein) via the AMPK-ULK1 and autophagy pathways; LAP in turn controls G-CSF and GM-CSF expression to support MDSC development. The AMPK-ULK1-autophagy-CEBPB-LAP pathway links tumor glycolysis to immune suppression. Glycolysis inhibition, AMPK-ULK1 pathway manipulation, isoform-specific Western blot, TNBC mouse models, MDSC flow cytometry Cell metabolism Medium 29805099
2013 C/EBPβ mediates both constitutive and LPS-induced transcription of murine SerpinB2 (PAI-2) in macrophages. A C/EBP element in the SerpinB2 proximal promoter is essential for LPS inducibility (shown by mutation analysis). C/EBPβ protein forms complexes with the SerpinB2 promoter upon LPS stimulation (shown by EMSA and ChIP). Both constitutive and LPS-induced SerpinB2 expression is abrogated in C/EBPβ-null MEFs and primary peritoneal macrophages. C/EBPβ-null MEFs and peritoneal macrophages, EMSA, ChIP, reporter promoter deletion/mutation analysis PloS one High 23472114
2019 PRMT7 interacts with and methylates C/EBPβ upon adipogenic induction and modulates accumulation of C/EBPβ at target sites in the PPARγ2 promoter. PRMT7 depletion promotes mitotic clonal expansion and adipogenesis, while PRMT7 overexpression attenuates these processes. PRMT7-/- MEFs show increased adipogenesis. Co-immunoprecipitation, methylation assay, ChIP at PPARγ2 promoter, PRMT7-/- MEFs, adipogenesis assays Biochemical and biophysical research communications Medium 31371025
2000 C/EBPβ and Elk-1 physically interact and synergistically transactivate the c-fos serum response element (SRE) in an Ras-dependent manner. The interaction requires the C-terminal domain of C/EBPβ and the N-terminal domain of Elk-1. In vivo co-immunoprecipitation demonstrated this interaction is dependent on activated Ras signaling. GST pulldown, co-immunoprecipitation (Ras-dependent), reporter assay (Gal4-SRF and SRE reporters), domain deletion mapping BMC cell biology Medium 11151091
2002 C/EBP-beta (NF-IL6) mediates hypoxia-induced iNOS expression in rat pulmonary microvascular smooth muscle cells. Mutation of a C/EBP motif at -910 bp of the rat iNOS promoter abolishes hypoxia-induced promoter activity. Hypoxia increases C/EBPβ DNA-binding activity measured by EMSA. EMSA, iNOS promoter C/EBP site mutation, reporter assay, hypoxia exposure model Circulation research Medium 11834703
2021 A δ-secretase-truncated APP fragment (C586-695) directly binds CEBPB, enhances its transcriptional activity and nuclear translocation, augmenting expression of APP, MAPT, δ-secretase, and inflammatory cytokines. Full-length APP does not associate with CEBPB. Blocking δ-secretase cleavage or clearing the fragment reduces CEBPB stimulation and Alzheimer's disease pathology. Co-immunoprecipitation, nuclear translocation assay, reporter assay for CEBPB transcriptional activity, viral overexpression mouse model, antibody clearance experiment Brain : a journal of neurology Medium 33880508
2019 DN-ATF5 associates with CEBPB and CEBPD in cells (shown by unbiased pull-down and mass spectrometry plus immunoblotting) and interferes with their transcriptional activity. CEBPB or CEBPD knockdown promotes apoptotic death of multiple cancer cell lines but not normal astrocytes. DN-ATF5 acts by blocking CEBPB/CEBPD homodimer and heterodimer formation. Pull-down coupled with mass spectrometry, immunoblotting, siRNA knockdown of CEBPB/CEBPD, reporter assays for transcriptional activity Molecular cancer research : MCR Medium 31676720
2015 MDR (multidrug-resistant) cells lack C/EBP-β LIP due to constitutive ubiquitination leading to lysosomal and proteasomal degradation. Loss of LIP drives MDR by increasing P-glycoprotein (Pgp) expression and attenuating ER stress-triggered cell death through the CHOP-caspase-3 axis. LIP overexpression reversed the MDR phenotype in vitro and in vivo. Ubiquitination assays, proteasome/lysosome inhibitors, LIP overexpression in vitro and in vivo orthotopic tumor model, Pgp expression, CHOP-caspase-3 axis analysis Journal of the National Cancer Institute Medium 25766403
2017 C/EBPβ in myeloid cells is required for sepsis-induced generation of immunosuppressive MDSCs. Myeloid-restricted C/EBPβ-deficient mice do not generate MDSCs upon sepsis, do not develop immunosuppression, and survive sepsis at higher rates. C/EBPβ directs a switch from pro-inflammatory to repressor myeloid phenotype, but is not required for steady-state myelopoiesis. Myeloid cell-specific Cre-lox C/EBPβ deletion, cecal ligation/puncture sepsis model, MDSC flow cytometry, adoptive transfer, colony assays Journal of leukocyte biology High 28476751
2022 NRF2 directly regulates CEBPB expression in NRF2-activated lung cancer cells; CEBPB cooperates with NRF2 to co-regulate genes involved in drug metabolism and detoxification, driving drug resistance. Comprehensive genomic analysis identified NRF2-CEBPB co-regulated genes enriched for drug resistance pathways. ChIP-seq, transcriptomic analysis of NRF2-activated lung cancer cells with CEBPB KO, drug resistance functional assays Journal of biochemistry Medium 35137113
2023 Autophagy (SQSTM1/p62-mediated) degrades CEBPB normally; autophagy deficiency leads to CEBPB accumulation, which in turn promotes transcription of SOCS1/3. Elevated SOCS1/3 inhibits JAK1-STAT6 pathway activation and M2 macrophage marker expression, demonstrating that autophagy controls macrophage M2 polarization through CEBPB degradation. Macrophage-specific Atg5 conditional KO mice, AD skin model, CEBPB ChIP for SOCS1/3 promoters, STAT6 phosphorylation assays, flow cytometry for M2 markers Cell reports High 37963021
2019 PGC1α binds CEBPB to promote CPT1A transcription and fatty acid oxidation (FAO), promoting radiation resistance in nasopharyngeal carcinoma. PGC1α/CEBPB/CPT1A constitutes a signaling axis for FAO activation. Co-immunoprecipitation of PGC1α and CEBPB, ChIP/reporter assays for CPT1A transcription, FAO assay, radiation resistance functional assay Cancer science Medium 30945396
2019 PAK4 enhances CEBPB phosphorylation on Thr-235, and CEBPB binds the -1093 to -991 bp region of the CLDN4 promoter to transcriptionally upregulate CLDN4 expression, promoting breast cancer cell migration and invasion. ChIP confirming CEBPB binding to CLDN4 promoter, PAK4 phosphorylation assay, siRNA knockdown, migration/invasion assays Biochemical and biophysical research communications Medium 30808546
2022 CEBPB binds the TRIM2 promoter and acts as an upstream transcription factor for TRIM2. TRIM2 promotes p53 ubiquitination and degradation, thereby reducing p53 stability. Epinephrine signaling via β2-adrenergic receptor regulates CEBPB expression, placing CEBPB as an epinephrine-responsive upstream regulator of the TRIM2/p53 axis. ChIP assay for CEBPB binding to TRIM2 promoter, co-immunoprecipitation, p53 ubiquitination assay, β2-adrenergic receptor antagonist Journal of translational medicine Medium 35672760
2004 The C/EBPβ isoforms LAP and LIP differentially regulate cell cycle progression in regenerating liver. Adenoviral overexpression of LAP delays S-phase entry with decreased cyclin A/E, PCNA, and CDK2 activity, via decreased C/EBPα ratio and c-jun levels. LIP overexpression leads to stronger/earlier induction of cyclin A/E and more robust C/EBPα and c-jun induction, but does not alter S-phase entry timing. Adenoviral isoform overexpression, partial hepatectomy mouse model, CDK2 activity assay, Western blot for cyclins/PCNA Hepatology Medium 15368440
2006 FUS-DDIT3 fusion oncogene in myxoid liposarcoma upregulates IL-6 expression in a C/EBPβ-dependent manner. siRNA knockdown of CEBPB transcripts abolishes FUS-DDIT3-induced IL-6 upregulation. ChIP revealed direct interaction between the IL-6 promoter and C/EBPβ protein in these cells. siRNA knockdown of CEBPB, ChIP assay, microarray, RT-PCR International journal of cancer Medium 15688424
2022 CEBPB binds the Pim-1 promoter and promotes Pim-1 transcription, which facilitates NLRP3 inflammasome activation and pyroptosis in glomerular podocytes in lupus nephritis. Knockdown of CEBPB suppresses NLRP3 inflammasome activation and IL-1β/IL-6 secretion; overexpression of Pim-1 reverses these effects. ChIP for CEBPB binding to Pim-1 promoter, Pim-1 overexpression rescue, shCEBPB lentivirus in MRL/lpr mice, NLRP3 inflammasome assays Mediators of inflammation Medium 36248187
2024 CEBPB directly binds the SERPINA1 gene promoter and promotes SERPINA1 transcription; SERPINA1 in turn activates the STAT3 signaling pathway to promote CRC proliferation and migration. This CEBPB-SERPINA1-STAT3 axis drives colorectal cancer progression. ChIP assay, luciferase reporter gene assay, STAT3 pathway analysis, functional assays in CRC cells Cell death discovery Medium 38710698

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1990 A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. The EMBO journal 1463 2112087
1992 IL-6 and NF-IL6 in acute-phase response and viral infection. Immunological reviews 472 1380488
1995 Conditional ectopic expression of C/EBP beta in NIH-3T3 cells induces PPAR gamma and stimulates adipogenesis. Genes & development 457 7557387
1995 Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice. The EMBO journal 380 7744000
2018 Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer. Cell metabolism 376 29805099
2014 Transcriptional regulation of adipocyte differentiation: a central role for CCAAT/enhancer-binding protein (C/EBP) β. The Journal of biological chemistry 294 25451943
1999 A C/EBP beta isoform recruits the SWI/SNF complex to activate myeloid genes. Molecular cell 276 10619021
1997 CREB controls LAP/C/EBP beta transcription. Molecular and cellular biology 175 9199295
1994 C/EBP beta regulation of the tumor necrosis factor alpha gene. The Journal of clinical investigation 161 7929820
2004 Ras induces mediator complex exchange on C/EBP beta. Molecular cell 147 14759369
2002 Mechanism of c-Myb-C/EBP beta cooperation from separated sites on a promoter. Cell 133 11792321
2006 Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. The Journal of clinical investigation 132 17111047
1998 Transcription factors C/EBP alpha, C/EBP beta, and CHOP (Gadd153) expressed during the differentiation program of keratinocytes in vitro and in vivo. The Journal of investigative dermatology 123 9506442
2010 Molecular symbiosis of CHOP and C/EBP beta isoform LIP contributes to endoplasmic reticulum stress-induced apoptosis. Molecular and cellular biology 94 20479126
2019 PGC1α/CEBPB/CPT1A axis promotes radiation resistance of nasopharyngeal carcinoma through activating fatty acid oxidation. Cancer science 93 30945396
2016 The circadian clock regulates autophagy directly through the nuclear hormone receptor Nr1d1/Rev-erbα and indirectly via Cebpb/(C/ebpβ) in zebrafish. Autophagy 88 27171500
2011 IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM. Blood 83 21389327
2011 Regulatory evolution through divergence of a phosphoswitch in the transcription factor CEBPB. Nature 82 22080951
2005 A transcriptional role for C/EBP beta in the neuronal response to axonal injury. Molecular and cellular neurosciences 79 15936952
1996 C/EBP-beta/LAP controls down-regulation of albumin gene transcription during liver regeneration. The Journal of biological chemistry 75 8703043
2006 Inducible activation of CEBPB, a gene negatively regulated by BCR/ABL, inhibits proliferation and promotes differentiation of BCR/ABL-expressing cells. Blood 74 16418324
2006 Conditional ablation of C/EBP beta demonstrates its keratinocyte-specific requirement for cell survival and mouse skin tumorigenesis. Oncogene 71 16205634
2012 Negative regulation of miR-145 by C/EBP-β through the Akt pathway in cancer cells. Nucleic acids research 67 22495929
2007 The interferon signaling network and transcription factor C/EBP-beta. Cellular & molecular immunology 66 18163952
2015 C/EBP-β-activated microRNA-223 promotes tumour growth through targeting RASA1 in human colorectal cancer. British journal of cancer 61 25867276
2004 C/EBP beta isoforms LIP and LAP modulate progression of the cell cycle in the regenerating mouse liver. Hepatology (Baltimore, Md.) 59 15368440
2019 Quercetin-Induced miR-369-3p Suppresses Chronic Inflammatory Response Targeting C/EBP-β. Molecular nutrition & food research 58 31338984
2022 Stress-induced epinephrine promotes epithelial-to-mesenchymal transition and stemness of CRC through the CEBPB/TRIM2/P53 axis. Journal of translational medicine 56 35672760
2006 C/EBP beta blocks p65 phosphorylation and thereby NF-kappa B-mediated transcription in TNF-tolerant cells. Journal of immunology (Baltimore, Md. : 1950) 54 16785565
2018 PDE/cAMP/Epac/C/EBP-β Signaling Cascade Regulates Mitochondria Biogenesis of Tubular Epithelial Cells in Renal Fibrosis. Antioxidants & redox signaling 53 29216750
2010 C/EBP-beta regulates endoplasmic reticulum stress-triggered cell death in mouse and human models. PloS one 52 20209087
2003 Subnuclear localization of C/EBP beta is regulated by growth hormone and dependent on MAPK. The Journal of biological chemistry 52 12821655
2002 Transcription factors C/EBP-beta and -delta regulate IL-6 production in IL-1beta-stimulated human enterocytes. Journal of cellular physiology 51 12115737
2002 C/EBP-beta, C/EBP-delta, PU.1, AML1 genes: mutational analysis in 381 samples of hematopoietic and solid malignancies. Leukemia research 50 11916518
2018 Chromosome 19 miRNA cluster and CEBPB expression specifically mark and potentially drive triple negative breast cancers. PloS one 49 30335837
1992 The CCAAT/enhancer binding protein (C/EBP alpha) gene (CEBPA) maps to human chromosome 19q13.1 and the related nuclear factor NF-IL6 (C/EBP beta) gene (CEBPB) maps to human chromosome 20q13.1. Genomics 49 1427819
2015 Endogenous prostaglandin E2 potentiates anti-inflammatory phenotype of macrophage through the CREB-C/EBP-β cascade. European journal of immunology 48 26118414
2011 Stat3 and CCAAT/enhancer binding protein beta (C/EBP-beta) regulate Jab1/CSN5 expression in mammary carcinoma cells. Breast cancer research : BCR 48 21689417
2004 Critical prosurvival roles for C/EBP beta and insulin-like growth factor I in macrophage tumor cells. Molecular and cellular biology 48 15060147
1992 Regulation of expression of the interleukin 6 gene: structure and function of the transcription factor NF-IL6. Ciba Foundation symposium 47 1385054
2005 Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression. International journal of cancer 45 15688424
2017 Frontline Science: Myeloid cell-specific deletion of Cebpb decreases sepsis-induced immunosuppression in mice. Journal of leukocyte biology 42 28476751
2015 The role of C/EBP-β LIP in multidrug resistance. Journal of the National Cancer Institute 42 25766403
2012 Inhibition of CD200R1 expression by C/EBP β in reactive microglial cells. Journal of neuroinflammation 42 22776069
2016 C/EBP β Mediates Endoplasmic Reticulum Stress Regulated Inflammatory Response and Extracellular Matrix Degradation in LPS-Stimulated Human Periodontal Ligament Cells. International journal of molecular sciences 41 27011164
2021 Metformin inhibits human non-small cell lung cancer by regulating AMPK-CEBPB-PDL1 signaling pathway. Cancer immunology, immunotherapy : CII 40 34837101
2007 A ribosomal S-6 kinase-mediated signal to C/EBP-beta is critical for the development of liver fibrosis. PloS one 40 18159255
2019 A novel PAK4-CEBPB-CLDN4 axis involving in breast cancer cell migration and invasion. Biochemical and biophysical research communications 39 30808546
2023 Macrophage autophagy deficiency-induced CEBPB accumulation alleviates atopic dermatitis via impairing M2 polarization. Cell reports 38 37963021
2019 Dominant-Negative ATF5 Compromises Cancer Cell Survival by Targeting CEBPB and CEBPD. Molecular cancer research : MCR 38 31676720
2018 Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer. Journal of experimental & clinical cancer research : CR 37 30482226
2021 Garcinia cambogia attenuates adipogenesis by affecting CEBPB and SQSTM1/p62-mediated selective autophagic degradation of KLF3 through RPS6KA1 and STAT3 suppression. Autophagy 36 34101546
2013 Reciprocal modulation of C/EBP-α and C/EBP-β by IL-13 in activated microglia prevents neuronal death. European journal of immunology 36 23881867
2009 C/EBP-beta modulates transcription of tubulointerstitial nephritis antigen in obstructive uropathy. Journal of the American Society of Nephrology : JASN 36 19297554
2021 A delta-secretase-truncated APP fragment activates CEBPB, mediating Alzheimer's disease pathologies. Brain : a journal of neurology 35 33880508
2015 C/EBPβ (CEBPB) protein binding to the C/EBP|CRE DNA 8-mer TTGC|GTCA is inhibited by 5hmC and enhanced by 5mC, 5fC, and 5caC in the CG dinucleotide. Biochimica et biophysica acta 35 25779641
2024 CEBPB-mediated upregulation of SERPINA1 promotes colorectal cancer progression by enhancing STAT3 signaling. Cell death discovery 33 38710698
2015 XBP1-Independent UPR Pathways Suppress C/EBP-β Mediated Chondrocyte Differentiation in ER-Stress Related Skeletal Disease. PLoS genetics 33 26372225
1999 C/EBP beta in rheumatoid arthritis: correlation with inflammation, not disease specificity. Clinical immunology (Orlando, Fla.) 33 10370372
2018 Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma. Lung cancer (Amsterdam, Netherlands) 32 29748013
2016 CD200 increases alternatively activated macrophages through cAMP-response element binding protein - C/EBP-beta signaling. Journal of neurochemistry 32 26670206
2003 Regulation of elastin gene transcription by interleukin-1 beta-induced C/EBP beta isoforms. American journal of physiology. Cell physiology 32 12890646
2021 Cell-Penetrating CEBPB and CEBPD Leucine Zipper Decoys as Broadly Acting Anti-Cancer Agents. Cancers 31 34065488
2022 CEBPB is required for NRF2-mediated drug resistance in NRF2-activated non-small cell lung cancer cells. Journal of biochemistry 28 35137113
2011 Role of C/EBP-β, p38 MAPK, and MKK6 in IL-1β-mediated C3 gene regulation in astrocytes. Journal of cellular biochemistry 27 21308746
2008 Loss of c/EBP-beta activity promotes the adaptive to apoptotic switch in hypoxic cortical neurons. Molecular and cellular neurosciences 27 18439838
2002 C/EBP-beta mediates iNOS induction by hypoxia in rat pulmonary microvascular smooth muscle cells. Circulation research 27 11834703
1996 Nuclear factor kappa B (NF-kappa B), nuclear factor interleukin-6 (NFIL-6 or C/EBP beta) and nuclear factor interleukin-6 beta (NFIL6-beta or C/EBP delta) are not sufficient to activate the endogenous interleukin-6 gene in the human breast carcinoma cell line MCF-7. Comparative analysis with MDA-MB-231 cells, an interleukin-6-expressing human breast carcinoma cell line. European journal of biochemistry 27 8774705
2011 C/EBP-α and C/EBP-β-mediated adipogenesis of human mesenchymal stem cells (hMSCs) using PLGA nanoparticles complexed with poly(ethyleneimmine). Biomaterials 26 21600648
2008 Translationally regulated C/EBP beta isoform expression upregulates metastatic genes in hormone-independent prostate cancer cells. The Prostate 26 18512730
2008 Corticosteroids induce COX-2 expression in cardiomyocytes: role of glucocorticoid receptor and C/EBP-beta. American journal of physiology. Cell physiology 26 18650268
2002 Proteasome inhibitors activate the transcription factors C/EBP-beta and delta in human intestinal epithelial cells. Biochemical and biophysical research communications 26 11779194
1991 The Interleukin-6-dependent DNA-binding protein gene (transcription factor 5: TCF5) maps to human chromosome 20 and rat chromosome 3, the IL6 receptor locus (IL6R) to human chromosome 1 and rat chromosome 2, and the rat IL6 gene to rat chromosome 4. Genomics 26 1889804
2023 CEBPB regulates the migration, invasion and EMT of breast cancer cells by inhibiting THBS2 expression and O-fucosylation. Human molecular genetics 25 36728807
2021 DNA hypermethylation contributes to colorectal cancer metastasis by regulating the binding of CEBPB and TFCP2 to the CPEB1 promoter. Clinical epigenetics 25 33892791
2020 microRNA-381-3p Confers Protection Against Ischemic Stroke Through Promoting Angiogenesis and Inhibiting Inflammation by Suppressing Cebpb and Map3k8. Cellular and molecular neurobiology 25 32297103
2009 Cyclic regulation of transcription factor C/EBP beta in human endometrium. Reproductive biology and endocrinology : RB&E 25 19222842
2023 Targeting Transcription Factors ATF5, CEBPB and CEBPD with Cell-Penetrating Peptides to Treat Brain and Other Cancers. Cells 23 36831248
2022 PGAM1 regulation of ASS1 contributes to the progression of breast cancer through the cAMP/AMPK/CEBPB pathway. Molecular oncology 23 35674458
2006 Differential roles of C/EBP beta regulatory domains in specifying MCP-1 and IL-6 transcription. Molecular immunology 23 16784777
2024 The CEBPB+ glioblastoma subcluster specifically drives the formation of M2 tumor-associated macrophages to promote malignancy growth. Theranostics 22 38994023
2021 Short-Chain Fatty Acid Decreases the Expression of CEBPB to Inhibit miR-145-Mediated DUSP6 and Thus Further Suppresses Intestinal Inflammation. Inflammation 22 34792688
2015 Accelerated apoptosis of peripheral blood monocytes in Cebpb-deficient mice. Biochemical and biophysical research communications 22 26168729
2025 CD36 promotes iron accumulation and dysfunction in CD8+ T cells via the p38-CEBPB-TfR1 axis in early-stage hepatocellular carcinoma. Clinical and molecular hepatology 21 40037690
2019 Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma. Frontiers in oncology 21 30775317
2019 Downregulated Long Noncoding RNA GAS5 Fails to Function as Decoy of CEBPB, Resulting in Increased GDF15 Expression and Rapid Ovarian Cancer Cell Proliferation. Cancer biotherapy & radiopharmaceuticals 21 31314588
2022 CircZDBF2 up-regulates RNF145 by ceRNA model and recruits CEBPB to accelerate oral squamous cell carcinoma progression via NFκB signaling pathway. Journal of translational medicine 20 35365168
2022 Inhibition of CEBPB Attenuates Lupus Nephritis via Regulating Pim-1 Signaling. Mediators of inflammation 20 36248187
2023 Melatonin alleviates the toxic effect of di(2-ethylhexyl) phthalate on oocyte quality resulting from CEBPB suppression during primordial follicle formation. Journal of hazardous materials 19 38008054
2022 CEBPB regulates the bile acid receptor FXR to accelerate colon cancer progression by modulating aerobic glycolysis. Journal of clinical laboratory analysis 18 36129029
2013 The transcription factor C/EBP-β mediates constitutive and LPS-inducible transcription of murine SerpinB2. PloS one 18 23472114
2024 Itraconazole inhibits tumor growth via CEBPB-mediated glycolysis in colorectal cancer. Cancer science 17 38278779
2018 Loss of Stemness, EMT, and Supernumerary Tooth Formation in Cebpb-/-Runx2+/- Murine Incisors. Scientific reports 17 29581460
2018 A two phase regulation of bone regeneration: IL-17F mediates osteoblastogenesis via C/EBP-β in vitro. Bone 17 30010083
2023 CircDYM attenuates microglial apoptosis via CEBPB/ZC3H4 axis in LPS-induced mouse model of depression. International journal of biological macromolecules 16 37944732
2023 IGF2 deficiency promotes liver aging through mitochondrial dysfunction and upregulated CEBPB signaling in D-galactose-induced aging mice. Molecular medicine (Cambridge, Mass.) 16 38017373
2019 PRMT7 deficiency enhances adipogenesis through modulation of C/EBP-β. Biochemical and biophysical research communications 16 31371025
2000 C/EBP beta and Elk-1 synergistically transactivate the c-fos serum response element. BMC cell biology 16 11151091
2024 Isoliquiritigenin alleviates neuropathic pain by reducing microglia inflammation through inhibition of the ERK signaling pathway and decreasing CEBPB transcription expression. International immunopharmacology 15 39488922
2022 Nintedanib Alleviates Experimental Colitis by Inhibiting CEBPB/PCK1 and CEBPB/EFNA1 Pathways. Frontiers in pharmacology 15 35910380

Missed literature

Know a paper Affinage missed for CEBPB? Flag it for the maintainers and the community.

No submissions yet.